
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Study Phase : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration
Details : DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 02, 2021
Lead Product(s) : Deferasirox
Therapeutic Area : Hematology
Highest Development Status : Phase II
Sponsor : Catalent Pharma Solutions
Deal Size : Undisclosed
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Abiraterone Acetate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Translational Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and Dose Escalation and Expansion Study of DST-2970
Details : Abiraterone Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 02, 2020
Lead Product(s) : Abiraterone Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Translational Drug Development
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : DST-0509
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DST-0509 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of beta-Thalassemia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2018
Lead Product(s) : DST-0509
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All